XJPX2934
Market cap48mUSD
Jan 17, Last price
1,604.00JPY
1D
0.50%
1Q
0.56%
IPO
-60.10%
Name
J Frontier Co Ltd
Chart & Performance
P/E
—
P/S
0.42
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
17.71b
+5.17%
Net income
-2.09b
L+9.82%
CFO
-1.44b
L-21.56%
Profile
J Frontier Co.,Ltd. engages in the healthcare sale, medical care sale, and healthcare marketing businesses in Japan. It is involved in various activities, including online medical care, medication guidance, as well as operates drug delivery platform, medical institutions, and operates dispensing pharmacy. The company engages in distribution of pharmaceuticals products as well as involved in marketing, logistics, and call center activities. J Frontier Co.,Ltd. was incorporated in 2008 and is based in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | |
| Income | |||||
Revenues | 17,714,904 5.17% | 16,844,572 41.83% | 11,876,681 39.84% | ||
Cost of revenue | 9,381,649 | 18,465,926 | 11,093,461 | ||
Unusual Expense (Income) | |||||
NOPBT | 8,333,255 | (1,621,354) | 783,220 | ||
NOPBT Margin | 47.04% | 6.59% | |||
Operating Taxes | 369,540 | 20,567 | 300,144 | ||
Tax Rate | 4.43% | 38.32% | |||
NOPAT | 7,963,715 | (1,641,921) | 483,076 | ||
Net income | (2,086,426) 9.82% | (1,899,919) -574.36% | 400,519 -5.74% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 762,509 | 228,585 | 2,441,631 | ||
BB yield | -6.60% | -2.08% | -22.96% | ||
| Debt | |||||
Debt current | 2,274,639 | 752,150 | 86,732 | ||
Long-term debt | 2,917,260 | 1,397,870 | 476,584 | ||
Deferred revenue | 32,835 | ||||
Other long-term liabilities | 33,044 | 2 | 4 | ||
Net debt | 3,378,933 | 411,228 | (2,452,329) | ||
| Cash flow | |||||
Cash from operating activities | (1,435,744) | (1,830,377) | (366,943) | ||
CAPEX | (91,156) | (104,687) | (10,462) | ||
Cash from investing activities | (1,792,539) | (1,132,734) | (860,094) | ||
Cash from financing activities | 3,390,891 | 1,451,117 | 2,564,597 | ||
FCF | 6,752,676 | (2,024,210) | (181,434) | ||
| Balance | |||||
Cash | 1,812,966 | 1,648,360 | 2,956,408 | ||
Long term investments | 90,432 | 59,237 | |||
Excess cash | 927,221 | 896,563 | 2,421,811 | ||
Stockholders' equity | (1,371,704) | 143,182 | 3,146,850 | ||
Invested Capital | 8,192,909 | 4,634,654 | 2,034,785 | ||
ROIC | 124.17% | 50.67% | |||
ROCE | 121.17% | 17.45% | |||
| EV | |||||
Common stock shares outstanding | 4,897 | 4,627 | 4,621 | ||
Price | 2,359.00 -0.46% | 2,370.00 3.00% | 2,301.00 | ||
Market cap | 11,552,080 5.34% | 10,966,523 3.14% | 10,632,143 | ||
EV | 15,397,742 | 11,615,435 | 8,206,732 | ||
EBITDA | 8,741,018 | (1,327,168) | 842,007 | ||
EV/EBITDA | 1.76 | 9.75 | |||
Interest | 27,251 | 11,109 | 1,449 | ||
Interest/NOPBT | 0.33% | 0.19% | |||